FinancialContent

Articles published by Aquestive Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST TLSA
News headline image
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
News headline image
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Tickers AQST
< Previous 1 2 3 4 Next >